You can reach Katie on Signal at palmer.01. Amid ongoing battles over alternate supplies of blockbuster weight loss drugs, Eli Lilly filed new lawsuits against four telehealth firms and their ...

Eli Lilly (LLY) is among the list of large-cap pharmaceutical companies that are awaiting the Trump administration's word on tariffs on the industry. Trump's Department of Commerce is looking into ...

Eli Lilly has unleashed another wave of litigation against four telehealth brands in its widening legal war with sellers of alternative versions of its popular diabetes and weight-loss drugs.

Eli Lilly has escalated its legal offensive against compounding ... Just last month, Lilly scored a major legal victory when a U.S. judge issued an injunction blocking pharmacies from manufacturing ...

Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main rival Wegovy from Novo Nordisk. Novo Nordisk has enlisted the aid of major ...

Being first to market with a drug can be crucial. Eli Lilly is proving that being second but better can also pay. Zepbound, the American firm’s weight-loss jab, was approved in its home country ...

Eli Lilly (LLY) is among the list of large-cap pharmaceutical companies ... stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

Now, let's get back to our question: Did Eli Lilly just say checkmate to Novo Nordisk? Well, an approval for an oral drug would represent a big victory. First, its likely many people would prefer ...

Eli Lilly recently announced the impressive results of its SURMOUNT-5 trial, highlighting Zepbound's efficacy over Wegovy in weight management. This promising development was disclosed alongside ...